Emergent BioSolutions Inc (NYSE:EBS) achieved a significant reduction in net leverage from 3.3 times to 1.9 times by the end of 2025. The company reported a strong adjusted EBITDA of $205 million, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results